Gilead and BioCurate work together to develop ‘Industry-Ready’ therapeutic projects
October 17, 2019
Gilead Sciences, Inc and BioCurate Pty Ltd agree to collaborate with the aim of increasing the quality and quantity of ‘industry-ready’ therapeutic projects.
BioCurate is very pleased to advise that it continues to build on its commitment to engage with major international industry partners with the recent signing of a Memorandum of Understanding with Gilead Sciences, Inc (Gilead).
Gilead is a research-based biopharmaceutical company that discovers, develops and commercialises innovative medicines in areas of unmet medical need, with operations in more than 35 countries world-wide.
This commitment will help ensure BioCurate’s new drug development programs are informed and aligned with addressing unmet patient and market needs, and provide potential future partnering opportunities.
The principles underpinning this collaboration are consistent with those BioCurate has already in place with other industry partners: i.e. a non-exclusive arrangement with the aim of increasing the quality and quantity of ‘industry-ready’ therapeutic projects emanating principally from the University of Melbourne and Monash University.